Awake VDL Intubation With Dexmedetomidine, a Case Series (DexAwake) (DexAwake)

Awake VDL Intubation With Dexmedetomidine, a Case Series

Early after the videolaryngoscope'(VDL) introduction in clinical practice, the awake videolaryngoscopic (A-VDL) intubation took place with and instead of the awake video-bronchoscopic (A- VBS) intubation. The awake intubation is a safe profile technique that was underused since the only instrumentation available was the fiberoptic bronchoscope (FOB) or more recently the video-bronchoscope (VBS). With the VDL diffusion, the awake intubation option has eventually turned into a more utilized procedure, with the potential to become a daily procedure. This was also due to dexmedetomidine (DEX) introduction in The Operating Room pharmacopeia. Several steps must be standardized in order to homogeneously apply an awake intubation protocol. A department protocol is recommended (awake intubation guidelines) but a low threshold for enrollment can be used to shorten and standardize the execution times. This study aims to create a protocol and measure the outcomes.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Early after the videolaryngoscope'(VDL) introduction in clinical practice, the awake videolaryngoscopic (A-VDL) intubation took place with and instead of the awake video-bronchoscopic (A- VBS) intubation. The awake intubation is a safe profile technique that was underused since the only instrumentation available was the fiberoptic bronchoscope (FOB) or more recently the video-bronchoscope (VBS). With the VDL diffusion, the awake intubation option has eventually turned into a more utilized procedure, with the potential to become a daily procedure. This was also due to dexmedetomidine (DEX) introduction in The Operating Room pharmacopeia.

The emergency use of rescue techniques after failed intubation throws the operator into the rare, but unwanted emergency "Front of Neck Access" (FONA) scenario, while a failed awake intubation brings (carry, get) the operator into the "patient not intubated but safely and spontaneously breathing" scenario, moving away from the events of hypoxic complications and death.

Several steps must be standardized in order to homogeneously apply an awake intubation protocol. First, the patients need to be clinically evaluated for difficult intubation predictors. Most of the articles about prediction only investigated the relationship between difficult intubation' predictors and direct laryngoscopy and they showed poor to moderate sensitivity and specificity (Toshiga Shiga, Vannucci) but, moving on VDL' world this relationship has changed as showed by Cortellazzi et al with an AUC for El Ganzouri Risk Index improving from 0.74 to 0.9 using DL and Glidescope respectively. In addition to these considerations, all the most recent Airway Management Guidelines has confirmed as unmissable the clinical evaluation of anthropometric and clinical DI predictors. (DAS) Along with measuring all the EGRI parameters, it is pivotal to examine any abnormality in the head, pharyngo-laryngeal, neck, spine, and abdominal anatomy. Previous neck irradiation, mass lesions, neck circumference, super-obesity, severe cervico-dorsal kyphosis, or past pharyngo-laryngeal surgery have to be considered and may not alter the EGRI score that is, incidentally, made -as the other predictors -for apparently normal patients (Shiga).

A department protocol is recommended (awake intubation guidelines) but a low threshold for enrollment can be used to shorten and standardize the execution times.

We retrospectively evaluated 24 patients (from January 2019 to June 2021). For descriptive purposes, there are five procedural "Times": T0, T1, T2, T3, T4 and T5. T 0 is the start of the dexmedetomidine charge dose and local oral-pharyngeal anesthetic. In T1, the GAG reflex check is performed. In T2 fentanyl or ketamine is delivered. In T3 the local anesthetic is nebulized on vocal cord and trachea, under videolaryngoscopic view. T4 is the tube passage through the vocal cords. T5 is the EtCo2 curve assessment. At the end outcomes were measured.

Study Type

Observational

Enrollment (Actual)

24

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Brescia, Italy
        • Spedali Civili

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Primary care clinic

Description

Inclusion Criteria:

  • Abnormality in the head, pharyngo-laryngeal, neck, spinal anatomy, super-obesity, El Ganzouri Risk Index > 6 or high risk for ab ingestis or hemorrhage (i.e.: tongue, pharynx-hypopharynx cancer lesions or arteriovenous malformations)

Exclusion Criteria:

  • Interdental distance <1 cm
  • Need for emergency airway stabilization.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The number of A-VDL success
Time Frame: from the starting of sedation to the end of the intubation procedure
This was defined as the ability to identify good or poor glottic view without rupture of sedation or change in Rass/Ramsay sedation level.
from the starting of sedation to the end of the intubation procedure
The number of A-VDL intubation successes
Time Frame: from the starting of sedation to the end of the intubation procedure
This was defined as the number of effective tube passages and airway stabilization.
from the starting of sedation to the end of the intubation procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of intubations allocated after A-VDL to VBS intubation.
Time Frame: from the starting of sedation to the end of the intubation procedure
Airway stabilization
from the starting of sedation to the end of the intubation procedure
The kind of drugs used and dosage
Time Frame: from the starting of sedation to the end of the intubation procedure
Type of drug and dosage
from the starting of sedation to the end of the intubation procedure
Level of sedation obtained
Time Frame: from the starting of sedation to the end of the intubation procedure
Rass/ Ramsay
from the starting of sedation to the end of the intubation procedure
Presence absence of memory of pain or discomfort during the procedure
Time Frame: from the starting of sedation to the end of the intubation procedure
Pain or discomfort remembered by the patient
from the starting of sedation to the end of the intubation procedure
Presence/absence of complications
Time Frame: from the starting of sedation to the end of the intubation procedure
procedure abandonment for reasons other than poor glottic visualization, desaturation above 90%, bradycardia above 40
from the starting of sedation to the end of the intubation procedure

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Minutes from the beginning of sedation until airway stabilization
Time Frame: from the starting of sedation to the end of the intubation procedure
Time in minutes
from the starting of sedation to the end of the intubation procedure
Cormack and Lehane score obtained
Time Frame: from the starting of sedation to the end of the intubation procedure
C&L
from the starting of sedation to the end of the intubation procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Elena Cagnazzi, MD, Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2019

Primary Completion (Actual)

July 1, 2020

Study Completion (Actual)

June 30, 2021

Study Registration Dates

First Submitted

June 15, 2023

First Submitted That Met QC Criteria

June 15, 2023

First Posted (Actual)

June 26, 2023

Study Record Updates

Last Update Posted (Actual)

June 26, 2023

Last Update Submitted That Met QC Criteria

June 15, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • DA001

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Awake Intubation

Clinical Trials on Awake intubation

Subscribe